EUVIMEDEUVIMED entdecken
Multizentrische StudieRandomisierte kontrollierte StudieÄquivalenzstudieOpen Access · CC BY-NC-ND 4.0

Efficacy and safety of withholding antimicrobial therapy in children with cancer, fever, and neutropenia, with a demonstrated viral respiratory infection: a randomized clinical trial

Juan P Torres, Carolina Ibañez, Romina Valenzuela, Salome Rivera, Veronica De la Maza, Milena Villarroel, Paulina Coria, Veronica Contardo, Ana M Álvarez, Carmen M Zubieta, Valentina Gutierrez, Karen Ducasse und 2 weitere

Clinical Microbiology and Infection · 2024

DOI: 10.1016/j.cmi.2024.04.007 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Clinical Microbiology and Infection, 2024. Verfasst von Juan P Torres und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Paediatrics, Hospital Dr. Luis Calvo Mackenna, Faculty of Medicine, Universidad de Chile, Santiago, Chile; Committee of Infectious Dise…. Hauptthemen laut MEDLINE: Respiratory Tract Infections, Virus Diseases, Neoplasms. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 23 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: CONICYT FONDECYT.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

OBJECTIVES: To validate the efficacy and safety of withholding antimicrobial therapy in a new cohort of children with cancer and febrile neutropenia (FN) having a demonstrated viral respiratory tract infection. METHODS: Prospective, multicenter, noninferiority, randomized study, approved by the ethical committee, in children presenting with FN at seven hospitals in Chile, evaluated at admission for diagnosis of bacterial and viral pathogens. Children who were positive for a respiratory virus, negative for a bacterial pathogen, and had a favourable evolution after 48-72 hours of antimicrobial therapy were randomized to either maintain or withhold antimicrobial therapy. The primary endpoint was the percentage of episodes with an uneventful resolution, whereas the secondary endpoints were days of fever, days of hospitalization, requirement of antimicrobial treatment readministration, sepsis, paediatric intensive care unit admission, and death. RESULTS: A total of 301 of 939 children with FN episodes recruited between March 2021 and December 2023 had a respiratory virus as a unique identified microorganism, of which 139 had a favourable evolution at 48-72 hours and were randomized, 70 to maintain and 69 to withdraw antimicrobial therapy. The median days of antimicrobial therapy was 5 (IQR 3-6) versus 3 (IQR 3-6) days (p < 0.001), with similar frequency of uneventful resolution 66/70 (94%) and 66/69 (96%); relative risk, 1.01; (95% CI, 0.93 to 1.09), absolute risk difference 0.01; (95% CI, -0.05 to 0.08) and similar number of days of fever and days of hospitalization. No cases of sepsis, paediatric intensive care unit admission, or death were reported. DISCUSSION: We validated the strategy of withdrawal antimicrobial therapy in children with FN and viral respiratory tract infection based on clinical and microbiological/molecular diagnostic criteria. This will enable advances in antimicrobial stewardship strategies with a possible future impact on antimicrobial resistance.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Respiratory Tract InfectionsVirus DiseasesNeoplasmsHumansMaleFemaleChildChild, PreschoolProspective StudiesChileFebrile NeutropeniaInfantWithholding TreatmentFeverTreatment OutcomeAnti-Infective AgentsAnti-Bacterial AgentsHospitalizationAdolescent

Stichwörter der Autor:innen

Antimicrobial stewardshipCancerChildrenFebrile neutropeniaRespiratory viral infection

Substanzen

Anti-Infective AgentsAnti-Bacterial Agents

Autor:innen und Institutionen

  • Department of Paediatrics, Hospital Dr. Luis Calvo Mackenna, Faculty of Medicine, Universidad de Chile, Santiago, Chile; Committee of Infectious Diseases, National Child Program of Antineoplastics Drugs Network (PINDA),…
  • Department of Paediatrics, Hospital Dr. Luis Calvo Mackenna, Faculty of Medicine, Universidad de Chile, Santiago, Chile.
  • Research Unit, Department of Paediatrics, Faculty of Medicine, Universidad de Chile, Santiago, Chile.
  • Department of Paediatrics, Hospital Dr. Roberto del Rio, Faculty of Medicine, Universidad de Chile, Santiago, Chile; Committee of Infectious Diseases, National Child Program of Antineoplastics Drugs Network (PINDA), Chi…
  • Department of Paediatrics, Hospital San Juan de Dios, Santiago, Chile; Committee of Infectious Diseases, National Child Program of Antineoplastics Drugs Network (PINDA), Chile.
  • Department of Paediatrics, Hospital Dr. Exequiel González Cortés, Santiago, Chile.

Förderung

  • CONICYT FONDECYT

Zitieren

APA

Torres, J. P., Ibañez, C., Valenzuela, R., Rivera, S., De la Maza, V., Villarroel, M., Coria, P., Contardo, V., Álvarez, A. M., Zubieta, C. M., Gutierrez, V., Ducasse, K., Martínez, D., & Santolaya, M. E. (2024). Efficacy and safety of withholding antimicrobial therapy in children with cancer, fever, and neutropenia, with a demonstrated viral respiratory infection: a randomized clinical trial. Clinical Microbiology and Infection. https://doi.org/10.1016/j.cmi.2024.04.007

Vancouver

Torres JP, Ibañez C, Valenzuela R, Rivera S, De la Maza V, Villarroel M, et al. Efficacy and safety of withholding antimicrobial therapy in children with cancer, fever, and neutropenia, with a demonstrated viral respiratory infection: a randomized clinical trial. Clinical Microbiology and Infection. 2024. doi:10.1016/j.cmi.2024.04.007

BibTeX
@article{Torres2024,
  author = {Torres, Juan P and Ibañez, Carolina and Valenzuela, Romina and Rivera, Salome and De la Maza, Veronica and Villarroel, Milena and Coria, Paulina and Contardo, Veronica and Álvarez, Ana M and Zubieta, Carmen M and Gutierrez, Valentina and Ducasse, Karen and Martínez, Daniela and Santolaya, Maria E},
  title = {Efficacy and safety of withholding antimicrobial therapy in children with cancer, fever, and neutropenia, with a demonstrated viral respiratory infection: a randomized clinical trial},
  journal = {Clinical Microbiology and Infection},
  year = {2024},
  doi = {10.1016/j.cmi.2024.04.007}
}
Kostenlos starten →